Monopar Therapeutics Inc. Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss
Monopar Therapeutics Inc. (MNPR) had Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss of $36.78 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss · last filed 2026-08-12
- 2026-06-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $36.78K.
- 2026-03-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $26.16K.
- 2025-12-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $2.28K.
- 2025-09-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $858.00.
| Period end | Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss |
|---|---|
| 2026-06-30 | $36.78K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $26.16K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $2.28K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $858.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.05K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $262.00 10-Q · filed 2025-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |